

PROVINCIAL FUNDING SUMMARY

Gilteritinib (Xospata) for Acute Myeloid Leukemia (pCODR 10202)

pERC Recommendation: Reimburse with clinical criteria and/or conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: June 4, 2020

This information is current as of September 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under negotiation with manufacturer		
AB	Under negotiation with manufacturer		
SK	Under negotiation with manufacturer		
MB	Under negotiation with manufacturer		
ON	Under negotiation with manufacturer		
NS	Under negotiation with manufacturer		
NB	Under negotiation with manufacturer		
NL	Under negotiation with manufacturer		
PEI	Under negotiation with manufacturer		

Under negotiation with manufacturer means the Pan-Canadian Pharmaceutical Alliance is conducting a joint pan-Canadian negotiation. For more information on the Pan-Canadian Pharmaceutical Alliance, please see <https://www.pcpacanada.ca/>. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.